BioSpace News Archive

BioSpace 40 Under 40

BioSpace’s 40 Under 40 honors 40 exemplary biotech and pharma professionals who have distinguished themselves in their companies and their field. All under the age of 40, these young leaders already demonstrate our industry’s values of innovation, impact and commitment to improving outcomes for patients.

March 31, 2025

Photo of attendees at the “Investor and Market Insights” panel at the 2025 Cell & Gene Therapy Summit

IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES

Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.

March 31, 2025

·

5 min read

·

BioSpace Insights

Success roadmap journey, milestone or career path achievement, route or pathway to achieve goals, accomplishment, assessment or way to success, businessman look at achievement milestone to success.

GLP-1

Novo Paints Murky Cardio Picture for Semaglutide Franchise

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower cardiovascular death and nonfatal stroke.

March 31, 2025

·

2 min read

·

Tristan Manalac

Climb up, hand help businessman build ladder

Diabetes

Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.

March 31, 2025

·

4 min read

·

Annalee Armstrong

Radiopharmaceuticals

5 Big Pharmas Push Boundaries in Radiopharmaceuticals

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.

March 31, 2025

·

9 min read

·

Tristan Manalac

A scientist with pill bottles in front of FDA headquarters

Regulatory

FDA Action Alert: Amgen, Aldeyra and Argenx

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

March 31, 2025

·

3 min read

·

Tristan Manalac

People

For Alltrna CEO Michelle Werner, Making Better Drugs Is Personal

Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

March 31, 2025

·

5 min read

·

Shawna Williams

Digits abstract background with connected line and dots, wave flow. Digital neural networks. Network and connection background for your presentation.

IN PARTNERSHIP WITH ECLIPSEBIO

Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development

AI offers tremendous potential but there are critical and time-consuming flaws in black box AI predictions.

March 31, 2025

·

7 min read

·

BioSpace Insights

Digital collage modern art. Hand giving and receiving money

Mergers & acquisitions

Bluebird Draws Another Suitor Amid Plans To Go Private

Ayrmid’s offer is 50% higher than bluebird’s previously announced deal with Carlyle and SK Capital Partners.

March 31, 2025

·

2 min read

·

Tristan Manalac

Blood transfusion from person to person, art collage.

Approvals

Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or IX.

March 31, 2025

·

2 min read

·

Tristan Manalac